Board notes Independent Director exit, appoints CFO, re-appoints Independent Director

Management Changes View source PDF Explain this filing

MANGALAM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.8%Reaction day

₹34.21

prior close

₹35.77

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.8%+4.6% vs market

Pharmaceuticals peers, median of 159sector-0.6%+4.4% vs sector

On the reaction day the stock moved 4.6 pts more than Nifty Microcap 250 and 4.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

+0.3

15m

-0.0

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.8-0.8+4.6-0.6+4.4

Next day

-0.7+1.8-2.5+1.2-1.9

-2.1+2.8-4.9+1.8-3.8

+1.4+2.3-0.8+1.3+0.1

-0.8+1.8-2.5+0.7-1.4

-3.8+0.3-4.1+0.0-3.9

-6.2+0.5-6.7-0.2-6.0

15d

-15.5-2.5-12.9-2.3-13.1

-5.7-6.3+0.6-4.4-1.3

-10.8-8.0-2.9-7.2-3.6

-14.8+8.3-23.1+2.7-17.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

At a February 6, 2026 board meeting, Mangalam Drugs noted the resignation of Independent Director Rukmesh P. Dhandhania effective January 16, 2026, citing retirement. The board appointed Jeevan M. Dalvi as Chief Financial Officer effective February 6, 2026. Dalvi is a commerce graduate with over two decades of finance experience. Dr. Praveen Saxena was also re-appointed as Independent Director for a second five-year term from March 21, 2026, subject to shareholder approval.

Likely market impact

New CFO with 20 plus years finance experience takes charge. One Independent Director exits; another gets re-appointed for continuity.